Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Mangiameli, David P ^a   Blansfield, Joseph A ^a   Kachala, Stephan ^a   Lorang, Dominique ^a   Schafer, Peter H ^b   Muller, George W ^b   Stirling, David I ^b   Libutti, Steven K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLIN; LENALIDOMIDE; OXALIPLATIN; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DRUG DERIVATIVE; PYRIDINE DERIVATIVE; THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; INTRAOCULAR TUMOR; LUNG METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; RAT; SURVIVAL RATE; TUMOR VASCULARIZATION; VASCULAR RING; ANIMAL; CELL MOTION; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECT; EYE TUMOR; IN VITRO STUDY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SPRAGUE DAWLEY RAT; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EYE NEOPLASMS; HUMANS; MELANOMA; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; THALIDOMIDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34547925624     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-38     Document Type: Article

References (19)

1. Singh AD Bergman L Seregard S Uveal melanoma: Epidemiologic aspects Ophthalmol Clin North Am 2005 18 1 75-84, viii. Review 10.1016/ j.ohc.2004.07.002 15763193
2. Diener-West M Reynolds SM Agugliaro DJ Caldwell R Cumming K Earle JD Hawkins BS Hayman JA Jaiyesimi I Jampol LM Kirkwood JM Koh WJ Robertson DM Shaw JM Straatsma BR Thoma J Collaborative Ocular Melanoma Study Group Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26 Arch Ophthalmol 2005 123 12 1639-43 10.1001/archopht.123.12.1639 16344433
3. Peters S Voelter V Zografos L Pampallona S Popescu R Gillet M Bosshard W Fiorentini G Lotem M Weitzen R Keilholz U Humblet Y Piperno-Neumann S Stupp R Leyvraz S Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients Ann Oncol 2006 17 4 578-83 10.1093/annonc/mdl009 16469752
4. Pingpank JF Libutti SK Chang R Wood BJ Neeman Z Kam AW Figg WD Zhai S Beresneva T Seidel GD Alexander HR Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic mlignancies J Clin Oncol 23 15 3465-74 2005 May 20 10.1200/ JCO.2005.00.927 15908655
5. Wilhelm SM Carter C Tang L Wilkie D McNabola A Rong H Chen C Zhang X Vincent P McHugh M Cao Y Shujath J Gawlak S Eveleigh D Rowley B Liu L Adnane L Lynch M Auclair D Taylor I Gedrich R Voznesensky A Riedl B Post LE Bollag G Trail PA BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 2004 64 7099-7109 10.1158/0008-5472.CAN-04-1443 15466206
6. Davies H Bignell GR Cox C Stephens P Edkins S Clegg S Teague J Woffendin H Garnett MJ Bottomley W Davis N Dicks E Ewing R Floyd Y Gray K Hall S Hawes R Hughes J Kosmidou V Menzies A Mould C Parker A Stevens C Watt S Hooper S Wilson R Jayatilake H Gusterson BA Cooper C Shipley J Hargrave D Pritchard-Jones K Maitland N Chenevix-Trench G Riggins GJ Bigner DD Palmieri G Cossu A Flanagan A Nicholson A Ho JW Leung SY Yuen ST Weber BL Seigler HF Darrow TL Paterson H Marais R Marshall CJ Wooster R Stratton MR Futreal PA Mutations of the BRAF gene in human cancer Nature (Lond.) 2002 417 949-54 10.1038/nature00766
7. Alavi A Hood JD Frausto R Stupack DG Cheresh DA Role of Raf in vascular protection from distinct apoptotic stimuli Science (Wash. DC) 2003 301 94-6 10.1126/science.1082015
8. Hood JD Bednarski M Frausto R Guccione S Reisfeld RA Xiang R Cheresh DA Tumor regression by targeted gene delivery to the neovasculature Science (Wash. DC) 2002 296 2404-7 10.1126/science.1070200
9. Wojnowski L Zimmer AM Beck TW Hahn H Bernal R Rapp UR Zimmer A Endothelial apoptosis in Braf-deficient mice Nat Genet 1997 16 293-7 10.1038/ng0797-293 9207797
10. Betsholtz C Insight into the physiological functions of PDGF through genetic studies in mice Cytokine Growth Factor Rev 2004 15 4 215-28 Review. 10.1016/j.cytogfr.2004.03.005 15207813
11. Bartlett JB Dredge K Dalgleish AG The evolution of thalidomide and its IMiD derivatives as anticancer agents Nat Rev Cancer 2004 4 4 314-22 Review 10.1038/nrc1323 15057291
12. Hideshima T Chauhan D Shima Y Raje N Davies FE Tai YT Treon SP Lin B Schlossman RL Richardson P Muller G Stirling DI Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 9 2943-50 2000 Nov 1 11049970
13. Mitsiades N Mitsiades CS Poulaki V Chauhan D Richardson PG Hideshima T Munshi NC Treon SP Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications Blood 2002 99 4525-4530 10.1182/ blood.V99.12.4525 12036884
14. Dredge K Horsfall R Robinson SP Zhang L-H Lu L Tang Y Shirley MA Muller G Schafer P Stirling D Dalgleish AG Bartlett JB Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvascular Research 2005 69 56-63 10.1016/j.mvr.2005.01.002 15797261
15. Dredge K Marriott JB Macdonald CD Man H-W Chen R Muller GW Stirling D Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects British Journal of Cancer 2002 87 1166-1172 10.1038/sj.bjc.6600607 12402158
16. Gandhi AK Kang J Naziruddin S Parton A Schafer PH Stirling DI Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly Leukemia Research 2006 30 849-858 10.1016/j.leukres.2006.01.010 16494942
17. Corral LG Haslett PA Muller GW Chen R Wong LM Ocampo CJ Patterson RT Stirling DI Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha Journal of Immunology 1999 163 1 380-386
18. Haslett PAJ Hanekom WA Muller G Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro J Infect Dis 2003 187 6 946-955 10.1086/368126 12660941
19. Solly K Wang X Xu X Strulovici B Zheng W Application of Real-Time Cell Electronic Sensing (RT-CES) Technology to Cell-Based Assays ASSAY and Drug Development Technologies 2004 2 4 363-372 10.1089/adt.2004.2.363